Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. DFTX
8. MU
9. IBM
10. HOOD

Go back to Merck (MRK), Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers

Merck (MRK) Tops Q1 EPS by 16c, Revenues Beat; Lowers FY20 EPS/Revenue Guidance Below Consensus

April 28, 2020 6:48 AM EDT

Merck (NYSE: MRK) reported Q1 EPS of $1.50, $0.16 better than the analyst estimate of $1.34. Revenue for the quarter came in at $12.06 billion versus the consensus estimate of $11.46 billion.

First-Quarter 2020 Worldwide Sales Were $12.1 Billion, an Increase of 11%; Excluding the Impact from Foreign Exchange, Sales Grew 13%KEYTRUDA Sales Grew 45% to $3.3 Billion; Excluding the Impact from Foreign Exchange, Sales Grew 46%Human Health Vaccines Sales Grew 14% to $2.2 Billion, Including the Effect of Timing; Excluding the Impact from Foreign Exchange, Sales Grew 16%First-Quarter 2020 GAAP EPS Was $1.26; First-Quarter Non-GAAP EPS Was $1.50Company is Active... More